Aethlon Medical (AEMD) Expected to Announce Earnings on Wednesday

Aethlon Medical (NASDAQ:AEMD) will likely be issuing its Q3 2026 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of ($2.01) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings results on Wednesday, November 12th. The medical equipment provider reported ($3.74) EPS for the quarter, missing the consensus estimate of ($1.70) by ($2.04). On average, analysts expect Aethlon Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aethlon Medical Stock Down 2.9%

AEMD opened at $2.33 on Wednesday. The company’s 50-day moving average price is $3.04 and its 200 day moving average price is $6.80. Aethlon Medical has a fifty-two week low of $2.22 and a fifty-two week high of $64.00. The firm has a market cap of $2.26 million, a price-to-earnings ratio of -0.10 and a beta of 1.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent filing with the Securities & Exchange Commission. 1.99% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.